Publications

Pancreatic stellate cell heterogeneity in cancer

Authors: D Ohlund, A Handly-Santana, E Elyada, G Biffi, DA Tuveson

E-pub date: 1 Aug 2016

Journal name: CANCER RESEARCH

RNAi and CRISPR/Cas9 based in vivo models for drug discovery

Authors: P Premsrirut, G Martin, L Dow, SY Kim, J Zuber, G Hannon, S Lowe

E-pub date: 1 Aug 2016

Journal name: EUROPEAN JOURNAL OF CANCER

NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.

Authors: IA McNeish, KK Lin, JX Sun, S Goble, A Oza, RL Coleman, CL Scott, G Konecny...

E-pub date: 1 Aug 2016

Journal name: CLINICAL CANCER RESEARCH

SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.

Authors: DA Tumbarello, MR Andrews, JD Brenton

E-pub date: 1 Aug 2016

Journal name: PLoS One

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial

Authors: AM Piskorz, KK Lin, J Morris, E Mann, A Oza, RL Coleman, DM O'Malley, M Fri...

E-pub date: 1 Aug 2016

Journal name: EUROPEAN JOURNAL OF CANCER

CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.

Authors: J Garcia-Corbacho, F Mouliere, H Carr, JA Morris, F Marrass, DG Gale, S Kum...

E-pub date: 1 Aug 2016

Journal name:

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

Authors: CA Parkinson, D Gale, A Piskorz, C Hodgkin, H Biggs, H Addley, P Moyle, S F...

E-pub date: 1 Aug 2016

Journal name: JOURNAL OF CLINICAL ONCOLOGY

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

Authors: C Gourley, J Green, H Gabra, I Vergote, B Basu, JD Brenton, U Bjorklund, AM...

E-pub date: 1 Aug 2016

Journal name: JOURNAL OF CLINICAL ONCOLOGY

Filters

Research Groups

Core Facilities

Start date

End date

Pancreatic stellate cell heterogeneity in cancer

RNAi and CRISPR/Cas9 based in vivo models for drug discovery

NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.

SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial

CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).

Themes

Filters

Research Groups

Core Facilities

Start date

End date

Pancreatic stellate cell heterogeneity in cancer

RNAi and CRISPR/Cas9 based in vivo models for drug discovery

NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.

SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial

CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).